UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-K ______________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35676 ______________________________________ PROTHENA CORPORATIO ...

Prothena Corporation (PRTA) reported fourth-quarter 2024 loss per share of $1.08, wider than the Zacks Consensus Estimate of a loss of $1.02.  In the year-ago quarter, the company posted a loss of $1.26 cents per share.The bottom line improved year over year due to higher revenues and lower expenses.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Revenues totaled $2.1 million, which missed the Zacks Consensus Estimate of $14 million. PRTA recorded revenues of $316,000 for the fourth q ...

Prothena Fourth Quarter and Year-End 2024 Financial Results February 20, 2025 4Q and FY24 Earnings Call Agenda | Welcome | Mark Johnson Vice President of Investor Relations | | --- | --- | | Opening Remarks | Gene Kinney, Ph.D. President and CEO | | R&D Update | Chad Swanson, Ph.D. Chief Development Officer | | Commercial Update | Brandon Smith Chief Operating Officer | | Financial Results | Tran Nguyen Chief Financial Officer and Chief Strategy Officer | | Closing Remarks | Gene Kinney, Ph.D. President and ...

Financial Data and Key Metrics Changes - Prothena reported a net cash used in operating and investing activities of $150.3 million for 2024, at the low end of the guidance range of $148 million to $160 million [56] - The net loss for 2024 was $122.3 million, also at the low end of the guidance range of $120 million to $135 million [56] - As of December 31, 2024, Prothena had $472.2 million in cash, cash equivalents, and restricted cash, aligning with the guidance of $468 million [58] Business Line Data and Key Metrics Changes - The company has four wholly-owned and four partnered programs across various stages of clinical development, focusing on neurodegenerative and rare peripheral amyloid diseases [10][11] - Birtamimab is positioned as a potential multi-billion dollar global commercial opportunity, with expectations for a BLA submission to the FDA by the second half of 2026 if positive results are achieved in the ongoing Phase 3 AFFIRM-AL trial [13][44] Market Data and Key Metrics Changes - In the U.S., there are approximately 16,000 diagnosed and treated AL amyloidosis patients, with around 13,000 having cardiac involvement, which is the segment at highest risk for early mortality [45] - The estimated diagnosed and treated population of Mayo Stage IV patients is close to 5,000 in the U.S. and over 5,000 in major European markets [46] Company Strategy and Development Direction - Prothena aims to create transformational therapies for significant unmet medical needs, leveraging partnerships to advance treatments while maintaining financial upside [10][11] - The company is focused on building commercial capabilities to support birtamimab as its first potential commercial product, with plans for independent commercialization in the U.S. [43][49] Management's Comments on Operating Environment and Future Outlook - Management highlighted 2025 as a transformational year with significant clinical readouts expected from both wholly-owned and partnered programs [62] - The company remains well-capitalized with a robust cash position, focusing on advancing clinical programs to become a fully integrated commercial biotechnology company [62] Other Important Information - Prothena received an $80 million payment from Bristol Myers Squibb for the exclusive global license of PRX019 in 2024 [57] - The company has a simple capital structure with zero debt, which supports its financial stability [58] Q&A Session Summary Question: What is considered the best and worst-case scenario for the Phase 3 AFFIRM-AL trial? - Management emphasized the significant unmet need in AL amyloidosis and the opportunity for birtamimab to demonstrate survival benefits, with a best-case scenario being a p-value of 0.10% or less [70][71] Question: Can you discuss the baseline characteristics of patients enrolled in AFFIRM-AL? - Approximately 80% of subjects in the AFFIRM-AL trial are on daratumumab, with a focus on Mayo Stage IV patients who are at the highest risk of early mortality [81] Question: What visibility do you have on long-term mortality trends beyond the randomized phase of the trials? - Management noted that while there were no ongoing trials for long-term follow-up, data from previous trials indicated significant survival benefits for patients treated with birtamimab [88] Question: How does the control arm in AFFIRM-AL compare to the control arm in ANDROMEDA? - The control arm in AFFIRM-AL is expected to behave similarly to the VITAL trial, with a median survival of around 8.3 months, and daratumumab's inclusion does not seem to impact early mortality [112][114] Question: Can you elaborate on the rationale for the 200 mg expansion cohort in PRX012? - The expansion cohort was created to meet patient demand, as enrolling the B cohorts requires screening a large number of patients due to the low prevalence of APOE homozygous carriers [124]

Prothena (PRTA) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $1.26 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.88%. A quarter ago, it was expected that this drug developer would post a loss of $1.18 per share when it actually produced a loss of $1.10, delivering a surprise of 6.78%.Over the last four quarters, the company has surpassed ...

Exhibit 99.1 PRESS RELEASE Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights DUBLIN, Ireland, February 20, 2025-- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the fourth quarter and full year 2024. In addition, the Company provided business highlights and 2025 fi ...

NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Prothena Corporation PLC (NASDAQ:PRTA) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms. If you are a long-term PRTA stockholder please contact Justin Kuehn, Esq. here, by email at justin@kuehn.law, or call (833) 672-0814.  The consu ...

A month has gone by since the last earnings report for Prothena (PRTA) . Shares have lost about 17.9% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Prothena due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Prothena Q3 Earnings Beat Estimates, Pipeline Progress in ...

Prothena Corporation (PRTA) reported a loss per share of $1.10 per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of $1.18.In the year-ago quarter, the company posted earnings of 38 cents per share, driven by higher revenues.Third-quarter 2024 revenues totaled $1 million, which missed the Zacks Consensus Estimate of $2 million. PRTA recorded revenues of $85 million in the third quarter of 2023 on the back of collaboration revenues from partner Bristol Myers Squibb ( ...

Prothena (PRTA) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.18. This compares to earnings of $0.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6.78%. A quarter ago, it was expected that this drug developer would post a loss of $1.01 per share when it actually produced earnings of $1.22, delivering a surprise of 220.79%.Over the last four quarters, the company has su ...